Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07117487 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
A Phase 3 study of Respiratory Syncytial Virus, sponsored by ModernaTX.
- Active
- Registry status
- Phase 3
- Development phase
- 507
- Enrollment target
- 11
- Study locations
NCT07117487 is a Phase 3 study of Respiratory Syncytial Virus that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 507 participants, above the 325-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (56% higher). The trial reports 11 study locations across 11 states.
The verdict
NCT07117487, a Phase 3 study of Respiratory Syncytial Virus, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 507 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1345
Study Locations (11)
Colorado
- Velocity Clinical Research, Denver - Denver
Florida
- Indago Research & Health Center, Inc. - Hialeah
Georgia
- Velocity Clinical Research, Savannah - Savannah
Indiana
- Velocity Clinical Research, Valparaiso - Valparaiso
Louisiana
- Velocity Clinical Research, Covington - Covington
Maryland
- Velocity Clinical Research, Rockville - Rockville
Nebraska
- Velocity Clinical Research, Lincoln - Lincoln
Oregon
- Velocity Clinical Research, Medford - Medford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2025-08-05 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07117487
The ClinicalTrials.gov registry entry for NCT07117487 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 325-participant average among 7 other Respiratory Syncytial Virus trials with a reported enrollment target (56% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus appearing as the primary indexed condition, and to 1 intervention - of which mRNA-1345 is the first listed.
NCT07117487 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Colorado, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07117487 about?
NCT07117487 is a clinical study titled "A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age". The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
What is the current status of trial NCT07117487?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 507 participants. The study started on 2025-08-05. Estimated completion is 2026-04-15.
What conditions does trial NCT07117487 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus.
What interventions are being tested in trial NCT07117487?
The interventions under investigation include: mRNA-1345 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07117487?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07117487 being conducted?
This trial has 11 study locations across Colorado, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ACTIVE NOT RECRUITING · Phase 1
-
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
ACTIVE NOT RECRUITING · Phase 2
-
Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults
COMPLETED · Phase 1
-
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
COMPLETED · Phase 2
-
A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Adult Subjects
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.